CARE Ratings

  • Market Cap: Small Cap
  • Industry: Capital Markets
  • ISIN: INE752H01013
  • NSEID: CARERATING
  • BSEID: 534804
INR
1,623.55
32.2 (2.02%)
BSENSE

Jun 12, 03:30 PM

BSE+NSE Vol: 18.67 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

18.67 k (-21.62%) Volume

Shareholding (Mar 2026)

FII

23.25%

Held by 97 FIIs

DII

31.38%

Held by 25 DIIs

Promoter

0.00%

Why is CARE Ratings Ltd falling/rising?

12-Jun-2026

As of 12-Jun, CARE Ratings Ltd's stock price is rising to Rs 1,623.55, driven by strong financial performance, including a 24.81% increase in profit after tax and high return on capital employed. Despite a drop in delivery volume, the stock remains liquid and has strong institutional support.

As of 12-Jun, CARE Ratings Ltd's stock price is rising, currently at Rs 1,623.55, reflecting an increase of Rs 32.2 or 2.02%. This upward movement can be attributed to several positive factors. The company has reported positive results for the last 11 consecutive quarters, with a significant growth in profit after tax (PAT) of 24.81% for the first nine months, amounting to Rs 145.40 crore. Additionally, the return on capital employed (ROCE) is at its highest level of 24.81%, and profit before tax (PBT) has also seen a substantial increase of 28.77%.<BR><BR>Moreover, the stock has outperformed its sector by 1.99% today and reached an intraday high of Rs 1,629, which is a 2.37% increase. The stock's performance over the past week and month shows positive returns of 0.95% and 2.45%, respectively, while it has demonstrated remarkable growth over three and five years, with increases of 141.92% and 170.10%. <BR><BR>Despite a decline in investor participation, as indicated by a 57.88% drop in delivery volume compared to the five-day average, the stock remains liquid enough for trading. The high institutional holdings at 54.63% suggest confidence from investors who possess the resources to analyze the company's fundamentals effectively. Overall, these factors contribute to the rising price of CARE Ratings Ltd's stock.

View full answer

How big is CARE Ratings?

11-Jun-2026

As of 10th June, CARE Ratings Ltd has a market capitalization of 4,916.00 Cr, with recent Net Sales of 473.07 Cr and a Net Profit of 171.18 Cr.

As of 10th June, CARE Ratings Ltd has a market capitalization of 4,916.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 473.07 Cr and a Net Profit of 171.18 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 806.27 Cr and Total Assets of 957.73 Cr.

View full answer

Who are in the management team of CARE Ratings?

11-Jun-2026

The management team of CARE Ratings includes Mehul Harshadray Pandya (Managing Director & CEO), Najib Shah (Chairman), and several independent and non-executive directors, along with Nehal Shah as Company Secretary. This diverse team provides strong governance and expertise to the company.

The management team of CARE Ratings includes the following key members:<BR><BR>1. **Mehul Harshadray Pandya** - Managing Director & CEO<BR>2. **Najib Shah** - Chairman & Independent Director<BR>3. **Venkatadri Chandrasekaran** - Independent Director<BR>4. **Adesh Kumar Gupta** - Non-Executive & Independent Director<BR>5. **Sonal Desai** - Non-Executive & Independent Director<BR>6. **M Mathisekaran** - Non-Executive & Independent Director<BR>7. **Gurumoorthy Mahalingam** - Independent Director<BR>8. **Sobhag Mal Jain** - Director<BR>9. **Nehal Shah** - Company Secretary & Compliance Officer<BR><BR>This team brings a diverse range of expertise and governance to the company.

View full answer

Who are the peers of the CARE Ratings?

11-Jun-2026

CARE Ratings' peers include Prudent Corp, IIFL Capital, Indian Energy Ex, ICRA, Indo Thai Sec., Share India Sec., Monarch Networth, and Geojit Fin. Ser., with varying management risks and growth rates; Indo Thai Sec. leads in 1-year returns at 29.54%, while Indian Energy Ex. has the lowest at -38.63%.

Peers: The peers of CARE Ratings are Prudent Corp, IIFL Capital, Indian Energy Ex, ICRA, Indo Thai Sec., Share India Sec., Monarch Networth, and Geojit Fin. Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prudent Corp and Indian Energy Ex, while Average management risk is found at IIFL Capital, Indo Thai Sec., Share India Sec., Monarch Networth, and Geojit Fin. Ser. Good management risk is attributed to ICRA and CARE Ratings. For Growth, Excellent growth is noted at Prudent Corp, Indo Thai Sec., and Monarch Networth, while Good growth is seen at IIFL Capital and Share India Sec. Below Average growth is reported for Indian Energy Ex, ICRA, and CARE Ratings. All peers have an Excellent capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indo Thai Sec. at 29.54%, while Indian Energy Ex has the lowest at -38.63%. CARE Ratings' own 1-year return of -16.00% is better than Indian Energy Ex but worse than Indo Thai Sec. Additionally, the six-month returns are negative for Indian Energy Ex, ICRA, Indo Thai Sec., and Share India Sec.

View full answer

What does CARE Ratings do?

10-Jun-2026

CARE Ratings Ltd is a leading credit rating agency in India, providing ratings and research services in the capital markets. As of March 2026, it reported net sales of ₹131 Cr and a net profit of ₹53 Cr, with a market cap of ₹4,916 Cr.

Overview: <BR>CARE Ratings Ltd is a leading credit rating agency in India, operating within the capital markets industry and classified as a small-cap company.<BR><BR>History: <BR>CARE Ratings Limited was incorporated as Credit Analysis & Research Limited (CARE) in 1993 and changed its name to CARE Ratings Limited on February 22, 2017. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 131 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 53 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 4,916 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 32 <BR>Dividend Yield: 0.49% <BR>Debt-Equity: -0.13 <BR>Return on Equity: 18.36% <BR>Price to Book: 5.25<BR><BR>Contact Details: <BR>Address: 4th Floor Godrej Coliseum, Somaiya Hospital Road Sion(E) Mumbai Maharashtra : 400022 <BR>Tel: 91-22-67543456 <BR>Email: care@careratings.com <BR>Website: http://www.careratings.com

View full answer

Should I buy, sell or hold CARE Ratings Ltd?

03-Jun-2026

Are CARE Ratings Ltd latest results good or bad?

15-May-2026

CARE Ratings Ltd's latest results show strong growth with a 47.16% increase in net profit and a 19.17% rise in revenue, but concerns about earnings volatility and high valuation suggest caution for investors. While existing shareholders may hold, new investors should be wary of the company's inconsistent profitability.

CARE Ratings Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹52.83 crores for Q4 FY26, which is a significant increase of 47.16% quarter-on-quarter and 23.98% year-on-year. Additionally, revenue grew by 19.17% year-on-year, reaching ₹130.67 crores, indicating strong business momentum. The operating margin also expanded to 46.50%, up from 35.98% in the previous quarter, showcasing improved profitability.<BR><BR>However, there are notable concerns regarding the company's earnings volatility. The profits have shown sharp swings over recent quarters, with a troubling decline of 36.65% in Q3 FY26 followed by the recovery in Q4. This pattern raises questions about the sustainability of growth and profitability. The return on equity (ROE) stands at 17.73%, which, while improved, remains below industry standards for capital-light financial services.<BR><BR>Overall, while the latest results show positive growth and margin expansion, the underlying volatility in earnings and the challenges in maintaining consistent profitability suggest that investors should approach with caution. The stock's current valuation appears high relative to its growth prospects, making it less attractive for new investors at this time. Existing shareholders may consider holding but should remain vigilant about future earnings trends.

View full answer

When is the next results date for CARE Ratings Ltd?

29-Apr-2026

The next results date for CARE Ratings Ltd is 13 May 2026.

The next results date for CARE Ratings Ltd is scheduled for 13 May 2026.

View full answer

Is CARE Ratings technically bullish or bearish?

05-Dec-2025

As of December 4, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly MACD and KST remain bearish, indicating mixed momentum.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating a bullish signal. However, the weekly MACD and KST remain bearish, suggesting caution. The Bollinger Bands show a mixed picture with a bullish monthly signal but a mildly bearish weekly signal. Overall, while there are some bullish indicators, the presence of bearish signals in the weekly time frame indicates a lack of strong momentum.

View full answer

How has been the historical performance of CARE Ratings?

02-Dec-2025

CARE Ratings has shown consistent growth in net sales and profit, with net sales increasing from 247.63 crore in March 2022 to 402.32 crore in March 2025, and profit after tax rising from 76.83 crore to 140.00 crore during the same period, reflecting strong financial health.

Answer:<BR>The historical performance of CARE Ratings shows a consistent growth trend in net sales and profit over the years, with the latest figures for March 2025 indicating net sales of 402.32 crore and a profit after tax of 140.00 crore.<BR><BR>Breakdown:<BR>CARE Ratings has demonstrated a steady increase in total operating income, rising from 247.63 crore in March 2022 to 402.32 crore in March 2025. This growth is accompanied by a corresponding rise in operating profit, which increased from 79.61 crore in March 2022 to 155.34 crore in March 2025, reflecting an operating profit margin that improved from 32.15% to 38.61% over the same period. Profit before tax also showed a positive trend, climbing from 98.63 crore in March 2022 to 192.27 crore in March 2025. The profit after tax followed suit, reaching 140.00 crore in March 2025, up from 76.83 crore in March 2022. On the balance sheet, total assets grew from 725.07 crore in March 2022 to 957.73 crore in March 2025, while total liabilities increased from 725.07 crore to 957.73 crore, indicating a stable financial position. Cash flow from operating activities has also improved, with a cash flow of 90.00 crore in March 2024, up from 68.00 crore in March 2022. Overall, CARE Ratings has shown robust financial health and growth in key performance metrics over the years.

View full answer

Has CARE Ratings declared dividend?

14-Nov-2025

Yes, CARE Ratings Ltd has declared an 80% dividend, amounting to ₹7 per share, with an ex-date of November 5, 2024. The company has shown positive total returns across various periods, with a total return of 270.99% over the last 5 years.

CARE Ratings Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 80%<BR>- Amount per share: 7<BR>- Ex-date: Nov-05-2024<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -2.14%, the dividend return was 0.50%, resulting in a total return of -1.64%.<BR><BR>Over the past 6 months, the price return was 4.39%, the dividend return was 0.52%, leading to a total return of 4.91%.<BR><BR>In the 1-year period, the price return was 13.28%, the dividend return was 0.59%, culminating in a total return of 13.87%.<BR><BR>For the 2-year period, the price return was 86.39%, the dividend return was 2.84%, which resulted in a total return of 89.23%.<BR><BR>In the last 3 years, the price return was 199.77%, the dividend return was 9.17%, resulting in a total return of 208.94%.<BR><BR>Over the past 4 years, the price return was 144.99%, the dividend return was 9.78%, leading to a total return of 154.77%.<BR><BR>In the 5-year period, the price return was 256.47%, the dividend return was 14.52%, culminating in a total return of 270.99%.<BR><BR>Overall, CARE Ratings has declared a substantial dividend while also demonstrating positive total returns across various periods, indicating a strong performance in both dividends and stock price appreciation.

View full answer

Who are the top shareholders of the CARE Ratings?

17-Jul-2025

The top shareholders of CARE Ratings include foreign institutional investors (23.74%), mutual funds (14.42%), and the Life Insurance Corporation of India (9.58%), with individual investors holding 25.48%. There are no pledged promoter holdings, and no single promoter has the highest stake.

The top shareholders of CARE Ratings include a mix of institutional and individual investors. Notably, foreign institutional investors (FIIs) hold 23.74% of the shares, while mutual funds account for 14.42% through five different schemes. The Life Insurance Corporation of India is the highest public shareholder, owning 9.58%. Additionally, individual investors collectively hold 25.48% of the company's shares. There are no pledged promoter holdings, and there is no single promoter with the highest holding.

View full answer

Is CARE Ratings overvalued or undervalued?

09-Jun-2025

As of August 21, 2023, CARE Ratings is considered very expensive and overvalued with a PE ratio of 38.63 and other key financial metrics indicating it trades at a premium, making it potentially unattractive for new investors despite a strong past year performance.

As of 21 August 2023, the valuation grade for CARE Ratings has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued based on its key financial ratios, which include a PE ratio of 38.63, an EV to EBIT of 36.40, and a Price to Book Value of 6.57. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, CARE Ratings' PE ratio is lower than CRISIL's 55.38 but higher than ICRA's 37.22, while its EV to EBITDA of 33.65 is also less favorable than CRISIL's 40.01. The PEG ratio of 1.07 indicates that the stock is relatively expensive in relation to its growth rate. Despite a strong performance in the past year, with a return of 73.57% compared to the Sensex's 7.58%, the current valuation suggests that CARE Ratings may not provide an attractive entry point for investors at this time.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

The company is Net-Debt Free

 
2

Poor long term growth as Net Sales has grown by an annual rate of 13.75% and Operating profit at 15.76% over the last 5 years

 
3

The company has declared Positive results for the last 11 consecutive quarters

4

With ROE of 18.4, it has a Very Expensive valuation with a 5.2 Price to Book Value

5

High Institutional Holdings at 54.63%

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Capital Markets

stock-summary
Market cap

INR 4,829 Cr (Small Cap)

stock-summary
P/E

29.00

stock-summary
Industry P/E

32

stock-summary
Dividend Yield

0.50%

stock-summary
Debt Equity

-0.13

stock-summary
Return on Equity

18.36%

stock-summary
Price to Book

5.12

Revenue and Profits:
Net Sales:
131 Cr
(Quarterly Results - Mar 2026)
Net Profit:
53 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.5%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.71%
0.90%
0.19%
6 Months
5.32%
0.92%
6.24%
1 Year
-12.05%
1.15%
-10.9%
2 Years
48.83%
2.73%
51.56%
3 Years
141.92%
7.85%
149.77%
4 Years
260.99%
18.07%
279.06%
5 Years
170.1%
11.97%
182.07%

Latest dividend: 8 per share ex-dividend date: Nov-19-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

10-Jun-2026 | Source : BSE

Allotment of 11250 equity shares pursuant to exercise of ESOP

Announcement under Regulation 30 (LODR)-Newspaper Publication

09-Jun-2026 | Source : BSE

Newspaper Publication

Announcement under Regulation 30 (LODR)-Newspaper Publication

08-Jun-2026 | Source : BSE

IEPF Newspaper Publication

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

CARE Ratings Ltd has declared 140% dividend, ex-date: 25 Jun 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.75%
EBIT Growth (5y)
15.76%
EBIT to Interest (avg)
72.27
Debt to EBITDA (avg)
0.14
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
0.44
Tax Ratio
26.20%
Dividend Payout Ratio
53.45%
Pledged Shares
0
Institutional Holding
54.63%
ROCE (avg)
22.17%
ROE (avg)
14.68%

Valuation key factors

Factor
Value
P/E Ratio
29
Industry P/E
32
Price to Book Value
5.25
EV to EBIT
26.09
EV to EBITDA
24.19
EV to Capital Employed
5.90
EV to Sales
10.09
PEG Ratio
1.18
Dividend Yield
0.49%
ROCE (Latest)
22.60%
ROE (Latest)
18.36%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 9 Schemes (16.95%)

FIIs

Held by 97 FIIs (23.25%)

Promoter with highest holding

None

Highest Public shareholder

Life Insurance Corporation Of India (9.55%)

Individual Investors Holdings

24.94%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 19.17% vs 21.63% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 23.98% vs 76.95% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "130.67",
          "val2": "109.65",
          "chgp": "19.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "60.76",
          "val2": "47.37",
          "chgp": "28.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.63",
          "val2": "0.60",
          "chgp": "5.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "52.83",
          "val2": "42.61",
          "chgp": "23.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "46.50%",
          "val2": "43.20%",
          "chgp": "3.30%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 17.32% vs 20.53% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 23.39% vs 26.12% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "230.28",
          "val2": "196.29",
          "chgp": "17.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "96.15",
          "val2": "77.55",
          "chgp": "23.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.21",
          "val2": "0.95",
          "chgp": "27.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "82.45",
          "val2": "66.82",
          "chgp": "23.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "41.75%",
          "val2": "39.51%",
          "chgp": "2.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 16.99% vs 21.17% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 25.08% vs 23.78% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "342.40",
          "val2": "292.67",
          "chgp": "16.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "136.49",
          "val2": "107.98",
          "chgp": "26.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.86",
          "val2": "1.51",
          "chgp": "23.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "118.35",
          "val2": "94.62",
          "chgp": "25.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "39.86%",
          "val2": "36.89%",
          "chgp": "2.97%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 17.59% vs 21.30% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.73% vs 36.53% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "473.07",
          "val2": "402.32",
          "chgp": "17.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "197.39",
          "val2": "155.34",
          "chgp": "27.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.49",
          "val2": "2.11",
          "chgp": "18.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "171.18",
          "val2": "137.24",
          "chgp": "24.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "41.73%",
          "val2": "38.61%",
          "chgp": "3.12%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoYstock-summary

Mar'26
Mar'25
Change(%)
Net Sales
130.67
109.65
19.17%
Operating Profit (PBDIT) excl Other Income
60.76
47.37
28.27%
Interest
0.63
0.60
5.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
52.83
42.61
23.98%
Operating Profit Margin (Excl OI)
46.50%
43.20%
3.30%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2026 is 19.17% vs 21.63% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 23.98% vs 76.95% in Mar 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
230.28
196.29
17.32%
Operating Profit (PBDIT) excl Other Income
96.15
77.55
23.98%
Interest
1.21
0.95
27.37%
Exceptional Items
0.00
0.00
Consolidate Net Profit
82.45
66.82
23.39%
Operating Profit Margin (Excl OI)
41.75%
39.51%
2.24%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 17.32% vs 20.53% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 23.39% vs 26.12% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
342.40
292.67
16.99%
Operating Profit (PBDIT) excl Other Income
136.49
107.98
26.40%
Interest
1.86
1.51
23.18%
Exceptional Items
0.00
0.00
Consolidate Net Profit
118.35
94.62
25.08%
Operating Profit Margin (Excl OI)
39.86%
36.89%
2.97%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 16.99% vs 21.17% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 25.08% vs 23.78% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
473.07
402.32
17.59%
Operating Profit (PBDIT) excl Other Income
197.39
155.34
27.07%
Interest
2.49
2.11
18.01%
Exceptional Items
0.00
0.00
Consolidate Net Profit
171.18
137.24
24.73%
Operating Profit Margin (Excl OI)
41.73%
38.61%
3.12%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 17.59% vs 21.30% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.73% vs 36.53% in Mar 2025

stock-summaryCompany CV
About CARE Ratings Ltd stock-summary
stock-summary
CARE Ratings Ltd
Small Cap
Capital Markets
CARE Ratings Limited was formerly incorporated as Credit Analysis & Research Limited (CARE) on April 21, 1993. The Company then changed its name from Credit Analysis & Research Limited to CARE Ratings Limited on February 22, 2017. Credit Analysis & Research Ltd (CARE) commenced its operations in 1993 has established itself as the leading credit rating agency of India.
Company Coordinates stock-summary
Company Details
4th Floor Godrej Coliseum, Somaiya Hospital Road Sion(E) Mumbai Maharashtra : 400022
stock-summary
Tel: 91-22-67543456
stock-summary
care@careratings.com
Registrar Details
Karvy Computershare Pvt Ltd, Karvy House , 46 Avenue 4, Street No 1, Banjara Hills, Hyderabad